Shares of JD Health (06618.HK) have risen more than 6% following news of a deepened strategic partnership.

As of the latest update, the stock is up 6.09% to HK$36.26, with a trading turnover of HK$441 million.

The catalyst for the move is an announcement regarding a significant upgrade in the collaboration between JD Health and Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. in the field of "AI + medical devices."

Building on strong growth in core categories like continuous glucose monitors (CGM) and ECG devices in the first half of the year, alongside successful co-developed products and exclusive sales initiatives, the two companies have launched a new three-year plan.

This plan targets the connection of 15 million smart health devices and aims to further integrate AI-powered medical equipment into the JD Health app and its HomeCare service system.

The initiative is designed to achieve a comprehensive upgrade across the entire chain, from device connectivity and data management to health services.

Since entering a comprehensive strategic partnership in March, JD Health and Yuyue Medical have been working towards a three-year sales target of 10 billion yuan, aiming to set a new industry benchmark for growth.

Results from the first half of the year have shown significant progress, with notable growth across several key categories including blood glucose management, cardiac monitoring, and respiratory oxygen therapy.

Specifically, sales of Yuyue's CGM devices and ECG monitors have surged by over 200% year-on-year, establishing them as high-growth segments within JD Health's medical equipment business.